TESARO (TSRO) Misses Q1 EPS by 31c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. INTC
9. JBLU
10. HOOD

Go back to TESARO (TSRO) Misses Q1 EPS by 31c

TESARO Announces First-Quarter 2017 Operating Results

May 9, 2017 4:06 PM EDT

ZEJULA approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underwayZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib in ovarian, lung and breast cancers to begin 2H 2017VARUBY® approved in Europe and launches to begin late 2Q 2017VARUBI® IV NDA re-submitted to FDA; approval anticipated late 2Q 2017 TSR-042 clinical program now open to enroll patients with MSI-H endometrial... More